New treatment for Alzheimer’s

Israel’s Neurim is conducting a Phase 2 trial of its Piromelatine treatment, for Alzheimer’s disease (AD). The 26-week trial will compare once-daily oral doses of Piromelatine to placebo in approximately 500 patients diagnosed with mild AD.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *